Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry

Fineline Cube May 14, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...

Company Drug

Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata

Fineline Cube May 14, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...

Company Deals

Meheco Acquires Golden Harvest for E-commerce Expansion

Fineline Cube May 14, 2025

China Meheco Group Co., Ltd (SHA: 600056) announced the acquisition of 100% stake in Beijing...

Company

JD Healthcare Reports 25.5% Revenue Growth in Q1 2025

Fineline Cube May 14, 2025

JD Healthcare (HKG: 6618), a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), released its...

Company Drug

Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China

Fineline Cube May 14, 2025

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...

Company

Legend Biotech’s Q1 2025 Results Highlight Carvykti Sales Growth

Fineline Cube May 14, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue...

Company Deals

Sanyou Biopharmaceuticals and TransReco Biotechnology Partner to Advance Novel Drug Formulations

Fineline Cube May 14, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransReco (Wenzhou) Biotechnology Co., Ltd. announced a strategic...

Company Deals

Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China

Fineline Cube May 14, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...

Company Drug

BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial

Fineline Cube May 14, 2025

Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...

Company Deals

InnoCare Pharma Partners with Westlake University for Innovative Drug Research

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced a strategic partnership agreement with Westlake...

Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Company Deals

Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility

Fineline Cube May 13, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...

Company Drug

Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025

Fineline Cube May 13, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...

Company

Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal

Fineline Cube May 13, 2025

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...

Company Deals Drug

Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007

Fineline Cube May 13, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...

Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Company Drug

BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment

Fineline Cube May 13, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Medical Device

United Imaging Healthcare Gains FDA Approval for uAngio AVIVA Interventional X-ray System

Fineline Cube May 13, 2025

China-based United Imaging Healthcare (UIH, SHA: 688271) announced that it has received marketing approval from...

Posts pagination

1 … 187 188 189 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.